The role of UCA1 and WRAP53 in diagnosis 
of hepatocellular carcinoma: A single-center 
case-control study

Amr Aly Abdelmoety; Mohamed Youssef Elhassafy; Rasha Said Omar Said; Ahmed Elsheaita; Manal Mohamed Mahmoud

doi:10.5114/ceh.2023.127569

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2023
vol. 9

Send email

Copy url:

abstract:

Original paper

The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study

Amr Aly Abdelmoety

¹

,

Mohamed Youssef Elhassafy

¹

,

Rasha Said Omar Said

²

,

Ahmed Elsheaita

³

,

Manal Mohamed Mahmoud

³

Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Egypt
Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt
Experimental and Clinical Internal Medicine, Medical Research Institute, Alexandria University, Egypt

Clin Exp HEPATOL 2023; 9, 2: 129-137

DOI: https://doi.org/10.5114/ceh.2023.127569

Online publish date: 2023/06/18

View full text Get citation

PlumX metrics:

Aim of the study:
Hepatocellular carcinoma (HCC) prognosis heavily depends on early diagnosis. We aimed to determine the role of serum urothelial carcinoma-associated 1 (UCA1) and wd repeat containing antisense to TP53 (WRAP53) as diagnostic tools of HCC.

Material and methods:
A case-control study including 90 subjects (30 patients having HCC, 30 patients having liver cirrhosis without HCC and 30 healthy controls) was performed. In all participants, the serum levels of UCA1 and WRAP53 were assessed by quantitative real-time polymerase chain reaction together with serumαa-fetoprotein (AFP).

Results:
Serum levels of both UCA1 and WRAP53 were upregulated in patients with HCC being significantly higher than in patients with liver cirrhosis and healthy control (p < 0.001). They were also correlated with some clinicopathological characteristics of HCC. Using the receiver operating curve, both UCA1 and WRAP53 showed higher diagnostic performance for HCC (AUC = 0.9, 73.3% sensitivity, 100% specificity and AUC = 0.85, 63.3% sensitivity, 80% specificity respectively) and their combination with AFP resulted in improved sensitivity and specificity (AUC = 0.97, 90% sensitivity, 100% specificity).

Conclusions:
Serum UCA1 and WRAP53 have the potential to be used alone, or in combination or with AFP, as diagnostic non-invasive biomarkers for HCC with accepted sensitivity and specificity. This study has been registered in clinicaltrials.gov with clinical trial registration number NCT05088811.

keywords:

The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study

Amr Aly Abdelmoety 1 , Mohamed Youssef Elhassafy 1 , Rasha Said Omar Said 2 , Ahmed Elsheaita 3 , Manal Mohamed Mahmoud 3

long non-coding RNA, UCA1, hepatocellular carcinoma, WRAP53

Amr Aly Abdelmoety

¹

,

Mohamed Youssef Elhassafy

¹

,

Rasha Said Omar Said

²

,

Ahmed Elsheaita

³

,

Manal Mohamed Mahmoud

³